Bayer AG (OTCMKTS:BAYRY) shares rose 0.3% on Thursday . The company traded as high as $21.21 and last traded at $21.17, approximately 275,819 shares traded hands during trading. A decline of 29% from the average daily volume of 388,760 shares. The stock had previously closed at $21.11.
Several equities analysts have recently issued reports on the company. ValuEngine downgraded Bayer from a “hold” rating to a “sell” rating in a research report on Saturday. Berenberg Bank upgraded Bayer from a “hold” rating to a “buy” rating in a research report on Tuesday, December 17th. Finally, Zacks Investment Research upgraded Bayer from a “sell” rating to a “hold” rating and set a $21.00 target price on the stock in a research report on Wednesday, November 6th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $21.00.
The business has a fifty day moving average price of $20.77 and a 200 day moving average price of $19.05. The company has a debt-to-equity ratio of 0.82, a current ratio of 1.29 and a quick ratio of 0.88. The company has a market capitalization of $78.22 billion, a price-to-earnings ratio of 11.59, a price-to-earnings-growth ratio of 0.97 and a beta of 1.09.
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Read More: Recession
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.